Femasys (FEMY) Cash from Investing Activities (2020 - 2026)
Femasys' (FEMY) quarterly Cash from Investing Activities came in at -$79138.0 in Q1 2026, up 18.08% YoY from -$67020.2 in Q1 2025, and up 59.77% on a QoQ basis from -$196715.0 in Q4 2025.
Femasys (FEMY) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Femasys (FEMY) has 7 years of Cash from Investing Activities data on file, last reported at -$79138.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 18.08% year-over-year to -$79138.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$612631.0 (up 28.28% YoY) and the FY2025 annual result came in at -$630098.0, up 25.68% from the prior year.
- Cash from Investing Activities grew to -$79138.0 in Q1 2026, from -$196715.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$8901.0 in Q1 2023 to a low of -$440028.0 in Q3 2024.
- A 5-year average of -$124023.1 and a median of -$96605.0 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 92.61% — and 2024, when it plunged 1519.6%.
- Tracing FEMY's Cash from Investing Activities over 5 years: stood at -$93877.0 in 2022, then soared by 52.17% to -$44899.0 in 2023, then slumped by 146.36% to -$110613.0 in 2024, then slumped by 77.84% to -$196715.0 in 2025, then jumped by 59.77% to -$79138.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$79138.0 (Q1 2026), -$196715.0 (Q4 2025), and -$239816.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -26.60 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -241.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -222.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -383.65 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -461.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -43.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -87.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -90.00 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -117.00 Mn |
| 10 | Femasys | 9.97 Mn | 8.53 Mn | 189,391.00 | -22,179.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79,138.00 |
| Mar 31, 2026 | -79,138.00 |
| Dec 31, 2025 | -196,715.00 |
| Dec 31, 2025 | -196,715.00 |
| Sep 30, 2025 | -239,816.00 |
| Sep 30, 2025 | -239,816.00 |
| Jun 30, 2025 | -96,962.00 |
| Jun 30, 2025 | -96,962.00 |
| Mar 31, 2025 | -96,605.00 |
| Mar 31, 2025 | -96,605.00 |
| Dec 31, 2024 | -110,613.00 |
| Dec 31, 2024 | -110,613.00 |
| Sep 30, 2024 | -440,028.00 |
| Sep 30, 2024 | -440,028.00 |
| Jun 30, 2024 | -206,963.00 |
| Jun 30, 2024 | -206,963.00 |
| Mar 31, 2024 | -90,160.00 |
| Mar 31, 2024 | -90,160.00 |
| Dec 31, 2023 | -44,899.00 |
| Dec 31, 2023 | -44,899.00 |